<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03142360</url>
  </required_header>
  <id_info>
    <org_study_id>4-2017-0129</org_study_id>
    <nct_id>NCT03142360</nct_id>
  </id_info>
  <brief_title>Effect of Beraprost Sodium (Berasil) on Hemodialysis</brief_title>
  <official_title>Effect of Beraprost Sodium (Berasil) on Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is no randomized control study to determine if the beneficial effects of beraprost
      sodium could improve the patency of arteriovenous fistula in hemodialysis patients.
      Therefore, this study is aimed to demonstrate the use of beraprost sodium can improve the
      patency of arteriovenous fistula in patients undergoing hemodialysis. This study is
      prospectively randomize controlled open-label trials in patients who newly made artificial
      arteriovenous fistula for hemodialysis. This study is a pilot study, and the target number of
      subjects is 60 in total, 30 in the treatment group and 30 in the control group.

      After randomization, the treatment group takes a beraprost sodium for 6 months and the
      control group does not take placebo.

      Treatment lasts for 6 months after dosing but continues until the patient changes the
      renal-replacement therapy method or falls under the exclusion criteria.

      The patient should visit at 1, 3, and 6 months after arteriovenous graft surgery to check the
      access site after graft surgery. The doppler ultrasound test is performed to measure the
      access blood flow rate and patency of arteriovenous fistula.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective randomized controlled open-labeled trial of patients undergoing
      hemodialysis under the diagnosis of end stage renal disease. The subjects were divided into
      the treatment group and the control group through random assignment under the condition of
      receiving hemodialysis steadily and followed up for 6 months. After randomization, the
      treatment group received beraprost sodium (Berasil) for 6 months (24 weeks) and beraprost
      sodium will be provided by Astellas Pharma Korea, Inc. Patients were randomly assigned within
      2 days after successful arteriovenous graft surgery, and the treatment group started taking
      120 mcg of Berasil, while the control group did not take placebo to replace beraprost sodium.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 5, 2017</start_date>
  <completion_date type="Anticipated">April 4, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 4, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Treatment group is randomly assigned to start taking 120 mcg of Berasil. On the other hand, the control group does not take anything.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AVF maturation rate</measure>
    <time_frame>3 months after arteriovenous graft surgery</time_frame>
    <description>Physiologic maturation of the AVF by the definition of AVF access blood flow ≥500mlL/min and AVF diameter ≥4mm at 3 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AVF maturation rate</measure>
    <time_frame>1 month after arteriovenous graft surgery</time_frame>
    <description>Physiologic maturation of the AVF by the definition of AVF access blood flow ≥500mlL/min and AVF diameter ≥4mm at a month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodialysis performed rate</measure>
    <time_frame>3 months after arteriovenous graft surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AVF failure rate</measure>
    <time_frame>6 months after arteriovenous graft surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding events</measure>
    <time_frame>6 months after arteriovenous graft surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Arteriovenous Fistula Patency</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within two days after successful arteriovenous graft surgery, the treatment group is randomly assigned to start taking 120 mcg of Berasil.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Treatment group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>On the other hand, the control group does not take anything.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beraprost sodium (Berasil)</intervention_name>
    <description>Within two days after successful arteriovenous graft surgery, the treatment group is randomly assigned to start taking 120 mcg of Berasil.</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who meet all of the following criteria

               1. Patient who newly made artificial arteriovenous fistula for hemodialysis

               2. Patients who agree to participate in the test and sign a consent form

               3. Patients who had diabetes

        Exclusion Criteria:

          -  Patients under 18 years old, 80 years old or older

          -  Patients with a high risk of bleeding (hemophilia, capillary weakness, upper
             gastrointestinal bleeding, urinary tract bleeding, hemoptysis, vitreous hemorrhage,
             etc.)

          -  Women who are pregnant or have a possibility of pregnancy

          -  Platelet count ≤ 75000

          -  Patients taking anticoagulants or antithrombotics

          -  Patients with galactose intolerance, lactase deficiency or glucose-galactose
             malabsorption
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jung Tak Park, M.D., Ph.D.</last_name>
    <phone>82-2-2228-2281</phone>
    <email>jtpark@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Division of Nephrology, Department of Internal Medicine Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jung Tak Park, M.D., Ph,D</last_name>
      <phone>82-2-2228-2281</phone>
      <email>jtpark@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Lin CC, Yang WC, Chen MC, Liu WS, Yang CY, Lee PC. Effect of far infrared therapy on arteriovenous fistula maturation: an open-label randomized controlled trial. Am J Kidney Dis. 2013 Aug;62(2):304-11. doi: 10.1053/j.ajkd.2013.01.015. Epub 2013 Mar 6.</citation>
    <PMID>23474008</PMID>
  </reference>
  <reference>
    <citation>Na KY, Kim DK, Kim SG, Lee YK, Lim CS. Effect of beraprost sodium on arterial stiffness in patients with type 2 diabetic nephropathy. Trials. 2013 Sep 2;14:275. doi: 10.1186/1745-6215-14-275.</citation>
    <PMID>24066672</PMID>
  </reference>
  <reference>
    <citation>Dixon BS, Beck GJ, Vazquez MA, Greenberg A, Delmez JA, Allon M, Dember LM, Himmelfarb J, Gassman JJ, Greene T, Radeva MK, Davidson IJ, Ikizler TA, Braden GL, Fenves AZ, Kaufman JS, Cotton JR Jr, Martin KJ, McNeil JW, Rahman A, Lawson JH, Whiting JF, Hu B, Meyers CM, Kusek JW, Feldman HI; DAC Study Group. Effect of dipyridamole plus aspirin on hemodialysis graft patency. N Engl J Med. 2009 May 21;360(21):2191-201. doi: 10.1056/NEJMoa0805840.</citation>
    <PMID>19458364</PMID>
  </reference>
  <reference>
    <citation>Vicil S, Erdoğan S. Beraprost sodium, a prostacyclin (PGI) analogue, ameliorates lipopolysaccharide-induced cellular injury in lung alveolar epithelial cells. Turk J Med Sci. 2015;45(2):284-90.</citation>
    <PMID>26084116</PMID>
  </reference>
  <reference>
    <citation>Arai T. Long-term effects of beraprost sodium on arteriosclerosis obliterans: a single-center retrospective study of Japanese patients. Adv Ther. 2013 May;30(5):528-40. doi: 10.1007/s12325-013-0030-7. Epub 2013 Jun 8.</citation>
    <PMID>23749750</PMID>
  </reference>
  <reference>
    <citation>Murakami M, Watanabe M, Furukawa H, Nakahara H. The prostacyclin analogue beraprost sodium prevents occlusion of bypass grafts in patients with lower extremity arterial occlusive disease: a 20-year retrospective study. Ann Vasc Surg. 2005 Nov;19(6):838-42.</citation>
    <PMID>16247707</PMID>
  </reference>
  <reference>
    <citation>Sakao S, Tanabe N, Kasahara Y, Tatsumi K. Long-term survival of Japanese patients with pulmonary arterial hypertension treated with beraprost sodium, an oral prostacyclin analogue. Intern Med. 2014;53(17):1913-20. Epub 2014 Sep 1.</citation>
    <PMID>25175122</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2017</study_first_submitted>
  <study_first_submitted_qc>May 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2017</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fistula</mesh_term>
    <mesh_term>Arteriovenous Fistula</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Beraprost</mesh_term>
    <mesh_term>Epoprostenol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

